Denali Therapeutics Q3 Swings to Profit; Shares Rise After Hours

MT newswire2026/11/03 21:42

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

05:42 PM EST, 11/03/2026 (MT Newswires) -- Denali Therapeutics (DNLI) reported Q3 earnings late Tuesday of $0.37 per diluted share, swinging from a loss of $0.74 a year earlier. Analysts polled by FactSet expected a loss of $0.31. Revenue for the quarter ended Sept. 30 was $17.8 million, compared with no revenue in the year-earlier period Analysts expected $12.2 million. The company expects Q4 net product revenue of $30.0 million to $32.0 million. Analysts expect $22.8 million. Shares of Denali Therapeutics rose more than 8% in after-hours trading.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26